Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/JAD-210383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biofilm-modified Prussian blue improves memory function in late-stage Alzheimer's disease mice with triple therapy.
Int J Pharm
December 2024
School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu 212013, PR China. Electronic address:
Alzheimer's disease (AD) is a neurodegenerative disease that is significantly characterized by cognitive and memory impairments, which worsen significantly with age. In the late stages of AD, metal ion disorders and an imbalance of reactive oxygen species (ROS) levels occur in the brain microenvironment, which causes abnormal aggregation of β-amyloid (Aβ), leading to a significant worsening of the AD symptoms. Therefore, we designed a composite nanomaterial of macrophage membranes-encapsulated Prussian blue nanoparticles (PB NPs/MM).
View Article and Find Full Text PDFIAPP blocks anti-breast cancer function of CD8T cells via targeting cuproptosis.
Front Immunol
December 2024
Medical College, Henan University of Chinese Medicine, Zhengzhou, China.
Background: Breast cancer (BRCA) is the most prevalent type of cancer worldwide. As a highly heterogeneous cancer, it has a high recurrence rate. Since its biological behavior can be regulated by immunity and cuprotosis, so exploring potential therapeutic target to mediate immunity and cuprotosis is of great significance for BRCA therapy.
View Article and Find Full Text PDFRecent Studies on Heterocyclic Cholinesterase Inhibitors Against Alzheimer's Disease.
Chem Biodivers
November 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
Article Synopsis
- Alzheimer's disease is a progressive neurodegenerative disorder affecting emotions, language, memory, and cognitive judgment, linked to factors such as amyloid beta plaques and tau tangles.
- Disruption of the cholinergic system plays a key role in the disease, making cholinesterase inhibitors crucial for treatment as they help maintain acetylcholine levels in the brain.
- This review highlights recent advancements in cholinesterase inhibitors with heterocyclic rings, focusing on their chemical structures and potential for future drug development in Alzheimer's treatment.
Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity.
Ageing Res Rev
January 2025
Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Central South University, Changsha 410008, PR China; Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha 410000, PR China; Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha 410008, PR China. Electronic address:
The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer's disease (AD) after their phase III trials reached endpoints.
View Article and Find Full Text PDFResearch progress on the association of insulin resistance with type 2 diabetes mellitus and Alzheimer's disease.
Metab Brain Dis
November 2024
Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, 310013, Zhejiang, P.R. China.
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that is characterized by insulin resistance and hyperglycemia. It is also known to be a risk factor for Alzheimer's disease (AD). Insulin plays a crucial role in regulating the body's metabolism and is responsible for activating the Phosphoinotide-3-Kinase (PI3K)/Protein Kinase B (Akt) signaling pathway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!